Steadview Capital

Steadview Capital is a London-headquartered global investment firm that takes high-conviction positions in late-stage and public-private crossover companies with a heavy India bias. The firm operates more like a hedge fund-style growth investor than a venture capital firm, with check sizes of $25M and above and a stage focus on Series C, Series D, and growth rounds that may transition into public market positions. Healthcare founders below late-stage growth should not approach; this is a firm for category leaders raising priced rounds with meaningful revenue scale.

The healthcare thesis is broad rather than specialized. Public commentary frames the firm as a generalist growth investor with selective exposure to digital health and consumer health in the Indian market. The firm is not AI-focused as a thematic lens, which means founders pitching primarily on AI architecture or model performance will find less native interest than founders pitching on revenue durability, market leadership, and a clear path to public markets. The right founder is the CEO of a category-leading Indian digital health platform with $30M+ ARR or comparable scale metrics, contemplating a pre-IPO round or a public-private hybrid.

Geographic advantage is straightforward: deep India coverage, strong London and global LP relationships, and credibility in cross-border listings. For an Indian healthcare growth-stage company contemplating a US or Indian listing path, Steadview is a known name on cap tables and can help signal seriousness to public market investors. For LatAm, MENA, or Africa-headquartered companies, the strategic fit is weaker.

The right entry path is through an investment banker handling the round, an existing late-stage co-investor, or a senior board member with London or Mumbai growth-stage relationships. Warm intros from earlier-stage VCs in India who have done business with Steadview are also viable. Decks should lead with revenue, gross margin, retention cohorts, and a credible 18 to 24 month path to either profitability or a listing event. AI narrative should be treated as supporting evidence for unit economics, not as the central thesis.

Caveats. The firm operates at a scale where founders without the right metrics will be triaged quickly; do not waste cycles approaching them at Series A or early B. Hedge fund-style investors can have shorter holding periods and more aggressive expectations on liquidity than traditional VCs; understand the implications for your board dynamics and exit timing. The healthcare track record is not as deep as that of pure-play healthcare growth funds, so for a deeply specialized clinical or therapeutics asset, dedicated healthcare growth investors will likely be a better lead. For an Indian digital health category leader at scale, Steadview is a credible name to have on the cap table.